MedPath

Hydrochlorothiazide

Generic Name
Hydrochlorothiazide
Brand Names
Accuretic, Actelsar Hct, Aldactazide, Altace HCT, Atacand, Atacand Hct, Avalide, Benicar Hct, Diovan Hct, Exforge Hct, Hyzaar, Ifirmacombi, Karvezide, Lopressor Hct, Lotensin Hct, Maxzide, Micardis-hct, Olmetec Plus, Tekturna Hct, Teveten HCT, Tribenzor, Urozide, Vaseretic, Viskazide, Zestoretic, Ziac
Drug Type
Small Molecule
Chemical Formula
C7H8ClN3O4S2
CAS Number
58-93-5
Unique Ingredient Identifier
0J48LPH2TH
Background

Hydrochlorothiazide is the most commonly prescribed thiazide diuretic. It is indicated to treat edema and hypertension. Hydrochlorothiazide use is common but declining in favour of angiotensin converting enzyme inhibitors. Many combination products are available containing hydrochlorothiazide and angiotensin converting enzyme inhibitors or angiotensin II receptor blockers.

Hydrochlorothiazide was granted FDA approval on 12 February 1959.

Indication

Hydrochlorothiazide is indicated alone or in combination for the management of edema associated with congestive heart failure, hepatic cirrhosis, nephrotic syndrome, acute glomerulonephritis, chronic renal failure, and corticosteroid and estrogen therapy. Hydrochlorothiazide is also indicated alone or in combination for the management of hypertension.

Associated Conditions
Calcium Nephrolithiasis, Cirrhosis of the Liver, Congestive Heart Failure (CHF), Diabetes Insipidus, Edema, Hypertension, Hypertension, Essential Hypertension, Hypokalemia caused by diuretics, Nephrotic Syndrome, Pre-Eclampsia, Premenstrual tension with edema, Renal tubular acidosis, Sodium retention, Stroke
Associated Therapies
-

The Effects of Renin Inhibition on Fibrinolytic Balance and Endothelial Function

Phase 4
Completed
Conditions
High Blood Pressure
Interventions
First Posted Date
2017-04-14
Last Posted Date
2017-08-25
Lead Sponsor
Vanderbilt University Medical Center
Target Recruit Count
31
Registration Number
NCT03115853
Locations
🇺🇸

VUMC, Nashville, Tennessee, United States

Anxiety-mediated Impairments in Large Elastic Artery Function and the Autonomic Nervous System

Phase 4
Terminated
Conditions
Anxiety
Hypertension
Interventions
First Posted Date
2017-04-12
Last Posted Date
2024-07-29
Lead Sponsor
University of Iowa
Target Recruit Count
35
Registration Number
NCT03109795
Locations
🇺🇸

University of Iowa, Iowa City, Iowa, United States

The Effect of Diuretics on Mineral and Bone Disorder in Chronic Kidney Disease Patients

Not Applicable
Conditions
Chronic Kidney Disease
Secondary Hyperparathyroidism
Interventions
First Posted Date
2017-03-17
Last Posted Date
2017-10-26
Lead Sponsor
University of Sao Paulo General Hospital
Target Recruit Count
52
Registration Number
NCT03082742
Locations
🇧🇷

Hospital das Clinicas, Sao Paulo, SP, Brazil

Compare the Pharmacokinetics of TAH(80/10/12.5) Tablet in Comparison to the Co-administration of Telmisartan, Amlodipine and Hydrochlorothiazide in Healthy Male Volunteers

Phase 1
Completed
Conditions
Healthy
Interventions
Drug: TWYNSTA(Telmisartan+Amlodipine besylate)
Drug: TAH Tablet (Telmisartan80/Amlodipine besylate10/Hydrochlorothiazide12.5)
Drug: Hydrochlorothiazide
First Posted Date
2017-01-26
Last Posted Date
2017-01-26
Lead Sponsor
IlDong Pharmaceutical Co Ltd
Target Recruit Count
44
Registration Number
NCT03032315
Locations
🇰🇷

Chonbuk National University Hospital, Chonbuk, Korea, Republic of

DD-study: Diet or Diuretics for Salt-sensitivity in Chronic Kidney Disease

Phase 4
Completed
Conditions
Chronic Kidney Disease
Interventions
First Posted Date
2016-08-23
Last Posted Date
2018-04-20
Lead Sponsor
Erasmus Medical Center
Target Recruit Count
28
Registration Number
NCT02875886
Locations
🇳🇱

ErasmusMC, Rotterdam, Netherlands

N-of-1 Trials for Blood Pressure Medications in Adults

Early Phase 1
Completed
Conditions
High Blood Pressure
Hypertension
Interventions
First Posted Date
2016-04-20
Last Posted Date
2019-03-26
Lead Sponsor
Columbia University
Target Recruit Count
10
Registration Number
NCT02744456
Locations
🇺🇸

Columbia University Medical Center, New York, New York, United States

Clinical Trial to Compare the Pharmacokinetics of TAH Tablet in Comparison to the Co-administration of Telmisartan, Amlodipine and Hydrochlorothiazide in Healthy Male Volunteers

Phase 1
Completed
Conditions
Healthy
Interventions
Drug: TAH Tablet (Telmisartan/Amlodipine besylate/Hydrochlorothiazide)
Drug: TWYNSTA(Telmisartan+Amlodipine besylate)
Drug: Hydrochlorothiazide
First Posted Date
2016-04-15
Last Posted Date
2017-01-26
Lead Sponsor
IlDong Pharmaceutical Co Ltd
Target Recruit Count
40
Registration Number
NCT02739672
Locations
🇰🇷

Chonbuk National University Hospital, Chonbuk, Korea, Republic of

Night Time Use of Thiazide Diuretics for Improved Reduction in Stone Risk in Stone Formers With Elevated Urine Calcium

Not Applicable
Completed
Conditions
Kidney Stones
Interventions
First Posted Date
2016-03-17
Last Posted Date
2023-04-27
Lead Sponsor
VA New York Harbor Healthcare System
Target Recruit Count
10
Registration Number
NCT02711670
Locations
🇺🇸

VA New York Harbor Healthcare System, New York, New York, United States

Treatment of OSA Associated Hypertension With Nebivolol or Hydrochlorothiazide

Phase 4
Completed
Conditions
Hypertension
Interventions
First Posted Date
2016-03-16
Last Posted Date
2020-10-19
Lead Sponsor
University of California, San Diego
Target Recruit Count
41
Registration Number
NCT02710071

Treatment of OSA Associated Hypertension With Alpha 2 Agonist or Diuretic

Phase 4
Completed
Conditions
Obstructive Sleep Apnea
Interventions
First Posted Date
2016-03-04
Last Posted Date
2020-12-04
Lead Sponsor
University of California, San Diego
Target Recruit Count
41
Registration Number
NCT02699125
© Copyright 2025. All Rights Reserved by MedPath